Amgen Inc (AMGN): Madhavan Balachandran , EVP, Operations of Amgen Inc sold 30,000 shares on May 4, 2016. The Insider selling transaction was reported by the company on May 5, 2016 to the Securities and Exchange Commission. The shares were sold at $154.12 per share for a total value of $4,623,624.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 3, 2016, Sean E Harper (EVP, Research & Development) sold 21,875 shares at $157.99 per share price.On May 3, 2016, David Baltimore (director) sold 3,312 shares at $157.21 per share price.Also, On Mar 4, 2016, Robert A Bradway (Chairman, CEO and President) sold 20,000 shares at $146.48 per share price.On Sep 2, 2015, Carbonnel Francois De (director) sold 5,000 shares at $153.84 per share price.
Shares of Amgen (AMGN) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -2.17 points or -1.39% at $154.18 with 30,48,430 shares getting traded. Post opening the session at $155.28, the shares hit an intraday low of $153.53 and an intraday high of $155.86 and the price vacillated in this range throughout the day. The company has a market cap of $115,823 M and the number of outstanding shares has been calculated to be 75,12,17,080 shares. The 52-week high of Amgen is $181.81 and the 52-week low is $130.09.
On Mar 2, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced May 13, 2016 as the ex-dividend date and fixed the record date on May 17, 2016. The payable date has been fixed on Jun 8, 2016.
Company has been under the radar of several Street Analysts.Amgen is Initiated by Citigroup to Neutral and the brokerage firm has set the Price Target at $165. The Rating was issued on Feb 25, 2016.Amgen is Reiterated by Argus to Buy while Lowering the Price Target of the company shares to $ 185 from a previous price target of $202 . The Rating was issued on Feb 8, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.